Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
The rapid evolution of SARS-CoV-2 variants has raised concerns with regard to their potential to escape from vaccine-elicited antibodies and anti-spike protein monoclonal antibodies. We report here on an analysis of sera from recovered patients and vaccinated individuals and on neutralization by Regeneron therapeutic monoclonal antibodies.
Article activity feed
-
-
SciScore for 10.1101/2021.02.05.430003: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Human sera: Convalescent sera and sera from individuals vaccinated at NYULH with BNT162b2 on day 0, day 7 and day 28 (7 days following the second injection) were collected from individuals through the NYU Vaccine Center with written consent under I.R.B. approval (IRB 20-00595 and IRB 18-02037) and were deidentified. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources anti-p24 mAb (AG3.0), anti-His mAb (Invitrogen) and anti-GAPDH mAb (Life Technologies) followed by goat anti-mouse HRP-conjugated second antibody … SciScore for 10.1101/2021.02.05.430003: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Human sera: Convalescent sera and sera from individuals vaccinated at NYULH with BNT162b2 on day 0, day 7 and day 28 (7 days following the second injection) were collected from individuals through the NYU Vaccine Center with written consent under I.R.B. approval (IRB 20-00595 and IRB 18-02037) and were deidentified. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources anti-p24 mAb (AG3.0), anti-His mAb (Invitrogen) and anti-GAPDH mAb (Life Technologies) followed by goat anti-mouse HRP-conjugated second antibody (Sigma). anti-Hissuggested: Noneanti-GAPDHsuggested: Noneanti-mousesuggested: NoneThe beads were then washed with PBS, resuspended in reducing Laemmle loading buffer, heated to 90°C and separated by SDS-PAGE and analyzed on an immunoblot probed with anti-p24 antibody (AG3.0) followed by goat anti-mouse HRP-conjugated secondly antibody. anti-p24suggested: Noneanti-mouse HRP-conjugated secondly antibody.suggested: NoneExperimental Models: Cell Lines Sentences Resources Cells: 293T cells were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin (P/S) at 37°C in 5% CO2. 293Tsuggested: NoneACE2.293T cells are clonal cell-lines established by stable co-transfection with pLenti.ACE2-HA followed by selection in 1 μg/ml puromycin, as previously described 23,25. ACE2.293Tsuggested: NoneSoftware and Algorithms Sentences Resources Quantification and Statistical Analysis: All experiments were performed in technical duplicates or triplicates and data were analyzed using GraphPad Prism (Version 8). GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-